Table of Contents Show
The healthcare diagnostics landscape is witnessing a significant shift toward home based solutions, and Inito’s recent funding announcement underscores this transformation. The Bengaluru based startup has successfully closed a $29 million Series B funding round, bringing its total equity capital to $45 million since inception.
Strategic Investment Backing
Bertelsmann India Investments led this substantial funding round, with continued support from Fireside Ventures, an existing investor in the company. This vote of confidence from prominent investors reflects the growing recognition of personalized, accessible healthcare solutions that empower individuals to monitor their health from home.
Pioneering Hormone Diagnostics
Since launching in 2021, Inito has distinguished itself through innovative technology that enables quantitative hormone testing without requiring laboratory visits. The company’s fertility monitor measures critical biomarkers including Follicle Stimulating Hormone, Estrogen, Luteinizing Hormone, and Pregnanediol Glucuronide. These measurements are analyzed through sophisticated artificial intelligence algorithms that interpret hormone patterns, providing users with clinically accurate insights into their reproductive health.
The impact has been substantial, with the company supporting pregnancy outcomes at a scale comparable to the entire IVF industry in the United States. This achievement demonstrates both the efficacy of their technology and the significant market demand for convenient, reliable home diagnostics.
Technological Innovation Through AI-Engineered Antibodies
What sets Inito apart is its approach to antibody development. Traditional diagnostic methods rely on antibodies produced through animal based processes, which are time consuming, expensive, and often lack consistency. Inito is leveraging computational protein design and machine learning to create AI-engineered antibodies that offer superior sensitivity and reliability. This technological advancement addresses fundamental limitations that have constrained innovation in diagnostics for decades.
Expanding Beyond Fertility
With this fresh capital infusion, Inito plans to broaden its diagnostic capabilities beyond fertility monitoring. The company is developing tests for testosterone levels, vitamin deficiencies, and thyroid function, positioning itself as a comprehensive hormone and health diagnostics platform. This expansion represents a strategic move toward becoming an essential tool for preventive healthcare and chronic condition management.
Global Footprint and Intellectual Property
Inito operates with teams across Dubai, Bengaluru, and London, reflecting its global ambitions. The company holds over 20 patents, establishing a strong intellectual property portfolio that protects its innovations and creates barriers to entry for competitors.
As healthcare continues evolving toward patient centric, data driven models, Inito’s vision of making clinical-grade diagnostics accessible at home positions the company at the forefront of this transformation. The substantial funding will accelerate product development and market expansion, potentially redefining how individuals engage with their health management.
Also Read: Kerala-Based Perfume Venture Klyne Raises Rs. 2 Crore Ahead of 2026 Launch
